Profile data is unavailable for this security.
About the company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
- Revenue in USD (TTM)7.09bn
- Net income in USD63.81m
- Incorporated1987
- Employees23.74k
- LocationGrifols SAC/ Jesus y Maria, 6BARCELONA 08022SpainESP
- Phone+34 935710000
- Fax+34 935710267
- Websitehttps://www.grifols.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Krystal Biotech Inc | 50.70m | 10.93m | 4.59bn | 229.00 | 1,820.55 | 5.84 | 272.30 | 90.61 | 0.0885 | 0.0885 | 1.84 | 27.58 | 0.0737 | -- | -- | 221,393.00 | 1.59 | -11.50 | 1.66 | -12.01 | 93.90 | -- | 21.56 | -492.85 | 17.55 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -373.63m | 4.89bn | 376.00 | -- | 11.27 | -- | -- | -19.93 | -19.93 | 0.00 | 20.39 | 0.00 | -- | -- | 0.00 | -74.49 | -62.09 | -97.21 | -74.81 | -- | -- | -- | -- | -- | -- | 0.2217 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Organon & Co | 6.26bn | 1.02bn | 5.04bn | 10.00k | 4.91 | -- | 4.01 | 0.8052 | 3.99 | 3.99 | 24.44 | -0.2738 | 0.5443 | 2.17 | 3.89 | 626,300.00 | 8.89 | 16.53 | 11.64 | 20.97 | 59.84 | 65.12 | 16.33 | 26.79 | 1.09 | 2.31 | 1.01 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Halozyme Therapeutics, Inc. | 829.25m | 281.59m | 5.07bn | 373.00 | 18.93 | 60.37 | 13.93 | 6.11 | 2.11 | 2.11 | 6.18 | 0.6611 | 0.464 | 1.69 | 3.56 | 2,223,199.00 | 15.75 | 18.22 | 16.90 | 21.97 | 76.80 | 79.05 | 33.96 | 39.36 | 5.50 | 139.09 | 0.9471 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 5.21bn | 550.00 | -- | -- | -- | 23.82 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Apellis Pharmaceuticals Inc | 396.59m | -528.63m | 5.76bn | 702.00 | -- | 29.17 | -- | 14.52 | -4.48 | -4.48 | 3.34 | 1.63 | 0.5121 | 0.5042 | 3.70 | 564,944.40 | -68.26 | -73.88 | -93.25 | -90.03 | 85.25 | -- | -133.29 | -326.49 | 2.50 | -59.78 | 0.6775 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Grifols SA - ADR | 7.09bn | 63.81m | 5.77bn | 23.74k | 67.76 | 0.7117 | 8.61 | 0.8133 | 0.097 | 0.097 | 10.54 | 9.23 | 0.3068 | 1.23 | 9.86 | 298,671.40 | 0.8408 | -- | 1.06 | -- | 37.84 | -- | 2.74 | -- | 1.29 | 1.56 | 0.5593 | -- | 8.71 | -- | -71.52 | -- | -- | -- |
| Ionis Pharmaceuticals Inc | 787.65m | -366.29m | 6.12bn | 927.00 | -- | 15.67 | -- | 7.77 | -2.56 | -2.56 | 5.50 | 2.68 | 0.2852 | 0.362 | 12.77 | 849,673.10 | -13.26 | -6.30 | -15.38 | -7.44 | 98.84 | 98.75 | -46.50 | -21.23 | 5.83 | -- | 0.7671 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Immunitybio Inc | 622.00k | -583.20m | 6.17bn | 628.00 | -- | -- | -- | 9,914.25 | -1.13 | -1.13 | 0.0012 | -0.875 | 0.0014 | -- | 0.246 | 990.45 | -134.71 | -112.76 | -377.77 | -316.07 | -- | -- | -93,866.88 | -37,700.74 | -- | -2.08 | 3.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Exelixis Inc | 1.85bn | 205.05m | 6.38bn | 1.31k | 33.87 | 3.04 | 27.70 | 3.45 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Elanco Animal Health Inc | 4.42bn | -1.23bn | 6.69bn | 9.30k | -- | 1.07 | -- | 1.51 | -2.50 | -2.50 | 8.96 | 12.63 | 0.2959 | 1.18 | 5.39 | 474,946.30 | -8.25 | -3.27 | -9.15 | -3.65 | 56.28 | 54.28 | -27.87 | -11.53 | 1.35 | 1.18 | 0.4813 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.73bn | 645.00 | -- | 21.60 | -- | 23.86 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Cytokinetics, Inc. | 7.53m | -526.24m | 6.83bn | 423.00 | -- | -- | -- | 906.47 | -5.45 | -5.45 | 0.078 | -3.80 | 0.0082 | -- | 10.53 | 17,801.42 | -57.23 | -43.14 | -63.72 | -47.22 | -- | -- | -6,988.63 | -540.47 | -- | -16.52 | 2.66 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Revolution Medicines Inc | 11.58m | -436.37m | 6.85bn | 378.00 | -- | 3.62 | -- | 591.87 | -3.77 | -3.77 | 0.1024 | 11.09 | 0.0081 | -- | 3.91 | 30,634.92 | -30.37 | -29.76 | -32.71 | -32.59 | -- | -- | -3,768.28 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.93bn | 2.80k | 22.70 | 1.88 | 7.08 | 1.80 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Data as of May 03 2024. Currency figures normalised to Grifols SA's reporting currency: US Dollar USD
33.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 19.79m | 7.57% |
| Millennium Management LLCas of 31 Dec 2023 | 15.74m | 6.02% |
| Brandes Investment Partners LPas of 31 Jan 2024 | 14.06m | 5.38% |
| Black Creek Investment Management, Inc.as of 31 Dec 2023 | 9.25m | 3.54% |
| Flat Footed LLCas of 31 Dec 2023 | 7.36m | 2.82% |
| Pictet Asset Management SAas of 31 Dec 2023 | 7.17m | 2.74% |
| First Trust Advisors LPas of 31 Dec 2023 | 4.68m | 1.79% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2023 | 4.33m | 1.66% |
| Whitebox Advisors LLCas of 31 Dec 2023 | 3.68m | 1.41% |
| Harris Associates LPas of 31 Dec 2023 | 2.76m | 1.05% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
